Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1396 to 1410 of 1975 results for nice guidelines

  1. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  2. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  3. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  4. COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 (NG186)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  5. Temperature control to improve neurological outcomes after cardiac arrest (HTG710)

    Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).

    HealthTech guidance
    Published
    23 January 2024
    View recommendations

    Sections for HTG710

  6. Head injury: assessment and early management (CG176)

    This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).

    Withdrawn guideline

  7. Depression in adults: recognition and management (CG90)

    This guideline has been updated and replaced by NICE guideline on depression in adults: treatment and management (NG222).

    Withdrawn guideline

  8. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA1074

  9. Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)

    This guideline has been updated and replaced by the NICE guideline on spinal metastases and metastatic spinal cord compression (NG234).

    Withdrawn guideline

  10. Stop smoking interventions and services (NG92)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  11. Smoking prevention in schools (PH23)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  12. Smoking: stopping in pregnancy and after childbirth (PH26)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  13. Smoking: preventing uptake in children and young people (PH14)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  14. Smoking: harm reduction (PH45)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  15. Smoking: acute, maternity and mental health services (PH48)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline